» Authors » Rogier C Buijsman

Rogier C Buijsman

Explore the profile of Rogier C Buijsman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 481
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zanini E, Forster-Gross N, Bachmann F, Brungger A, McSheehy P, Litherland K, et al.
Front Oncol . 2024 Aug; 14:1447807. PMID: 39184047
Background: Threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) are common essential kinases that collaborate in activating the spindle assembly checkpoint (SAC) at the kinetochore, ensuring appropriate chromosome alignment...
2.
Houweling M, Giczewska A, Abdul K, Nieuwenhuis N, Kucukosmanoglu A, Pastuszak K, et al.
Neurooncol Adv . 2023 Jul; 5(1):vdad073. PMID: 37455945
Background: IDH-wildtype glioblastoma (GBM) is a highly malignant primary brain tumor with a median survival of 15 months after standard of care, which highlights the need for improved therapy. Personalized...
3.
Conboy C, Yonkus J, Buckarma E, Mun D, Werneburg N, Watkins R, et al.
J Hepatol . 2022 Sep; 78(1):142-152. PMID: 36162702
Background & Aims: There is an unmet need to develop novel, effective medical therapies for cholangiocarcinoma (CCA). The Hippo pathway effector, Yes-associated protein (YAP), is oncogenic in CCA, but has...
4.
Clemente G, Antunes I, Kurhade S, van den Berg M, Sijbesma J, van Waarde A, et al.
J Nucl Med . 2021 Mar; 62(8):1163-1170. PMID: 33712529
Arginase hydrolyzes L-arginine and influences levels of polyamines and nitric oxide. Arginase overexpression is associated with inflammation and tumorigenesis. Thus, radiolabeled arginase inhibitors may be suitable PET tracers for staging...
5.
Grobben Y, de Man J, van Doornmalen A, Muller M, Willemsen-Seegers N, Vu-Pham D, et al.
Front Immunol . 2021 Feb; 11:609490. PMID: 33584686
Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance...
6.
Perez-Pardo P, Grobben Y, Willemsen-Seegers N, Hartog M, Tutone M, Muller M, et al.
FEBS J . 2021 Jan; 288(14):4311-4331. PMID: 33471408
Parkinson's disease patients suffer from both motor and nonmotor impairments. There is currently no cure for Parkinson's disease, and the most commonly used treatment, levodopa, only functions as a temporary...
7.
den Ouden J, Zaman G, Dylus J, van Doornmalen A, Mulder W, Grobben Y, et al.
Oncotarget . 2020 Dec; 11(49):4570-4581. PMID: 33346216
Background: In epithelial ovarian cancer (EOC), 15-20% of the tumors do not respond to first-line chemotherapy (paclitaxel with platinum-based therapy), and in recurrences this number increases. Our aim is to...
8.
Grobben Y, Uitdehaag J, Willemsen-Seegers N, Tabak W, de Man J, Buijsman R, et al.
J Struct Biol X . 2020 Jul; 4:100014. PMID: 32647818
Arginase-1 is a manganese-dependent metalloenzyme that catalyzes the hydrolysis of L-arginine into L-ornithine and urea. Arginase-1 is abundantly expressed by tumor-infiltrating myeloid cells that promote tumor immunosuppression, which is relieved...
9.
Grobben Y, Willemsen-Seegers N, Uitdehaag J, de Man J, van Groningen J, Friesen J, et al.
SLAS Discov . 2020 May; 25(9):1018-1025. PMID: 32418491
Arginase-1, which converts the amino acid L-arginine into L-ornithine and urea, is a promising new drug target for cancer immunotherapy, as it has a role in the regulation of T-cell...
10.
Uitdehaag J, Kooijman J, de Roos J, Prinsen M, Dylus J, Willemsen-Seegers N, et al.
Mol Cancer Ther . 2018 Nov; 18(2):470-481. PMID: 30381447
Kinase inhibitors form the largest class of precision medicine. From 2013 to 2017, 17 have been approved, with 8 different mechanisms. We present a comprehensive profiling study of all 17...